lactis was replaced with a synthetic human IL-10 gene. To this end, the thymidilate synthase ( thyA) gene of L. We engineered a strain exhibiting biological containment. In both models, the effect was strictly dependent on delivery of live bacteria. Also, daily administration of the engineered strain prevented the onset of colitis, normally associated with the IL-10 knockout genotype. lactis led to a 50% reduction in inflammation. In the Dextran Sulphate Sodium (DSS)-induced chronic colitis intragastric administration of mIL-10-secreting L. lactis mediated topical delivery of IL-10. We used two mouse models for IBD to evaluate the efficacy of L. Both treatments suffered a serious drawback from the fact that they had to be administered systemically and thus caused potentially serious side effects. Despite initial successes with intravenous addition of IL-10, this treatment was abandoned in later trials. Systemic treatment with infliximab, a monoclonal antibody that binds TNFα is among the most potent therapies for Crohn's disease.
0 Comments
Leave a Reply. |